BI 144807
Alternative Names: BI-144807Latest Information Update: 04 Nov 2017
At a glance
- Originator Boehringer Ingelheim Pharmaceuticals
- Class Antiallergics; Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Wet age-related macular degeneration
- No development reported Allergic rhinitis; Asthma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Allergic-rhinitis(In volunteers) in Germany (PO, Tablet)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Asthma(In volunteers) in Germany (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Allergic-rhinitis(In volunteers) in Germany (PO, Liquid)